Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2024 Q2 | Jul 1, 2024 | Protean Funds | 0.0% | 24.3% | ACAST.ST, AMBEA.ST, AUTO.OL, CAMX.ST, CGCBV.HE, CINT.ST, DEVYSER.ST, FASAD.ST, ITAB.ST, KEMIRA.HE, KOJAMO.HE, METSB.HE, NETEL.ST, NORVA.ST, PROACT.ST, RAY.ST, REJL.ST, TIE1V.HE, VAIAS.HE, VALMT.HE | AI, inflation, Nordics, risk management, small cap, value | Manager views AI as a classic boom-bust cycle, comparing it to historical manias. Chat-GPT usage is already declining and trillion-dollar AI investments may take years to generate returns above cost of capital. | TRUE.ST NORVA.ST CAMX.ST METSB.HE |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Fund Letters | Protean Select | Camurus | Health Care | Pharmaceuticals | Bull | Stockholm Stock Exchange | Acromegaly, Addiction Treatment, biotechnology, drug delivery, franchise expansion, pharmaceuticals, Platform Technology, Sweden | View Pitch |
| Apr 13, 2026 | Fund Letters | Protean Funds | Camurus | Health Care | Pharmaceuticals | Bull | Stockholm Stock Exchange | Acromegaly, biotechnology, Brixadi, Buvidal, Long-release Technology, pharmaceuticals, platform company, Sweden | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||